quaratusugene ozeplasmid

PreclinicalBiologic

GGenprex, Inc.

quaratusugene ozeplasmid is one of 24 biologic programs targeting Maintenance Therapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Maintenance TherapyRecruiting

Maintenance TherapyPreclinical

Recruiting

Competition

Competitive Landscape

23 competitors in Maintenance Therapy

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 3

3 2

Rinvoq

AbbVie

Phase 3

1 3

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

9 4

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

4 5

Cytoxan

BBaxter Healthcare Corporation

Phase 3

1 6

Opzelura

DDizal Pharmaceuticals

Phase 3

1 7

PD-1 Inhibitor

Johnson & Johnson

Phase 3

3 8

Beyfortus

BeiGene

Phase 2

4 9

Libtayo

Regeneron

Phase 2

2 10

Rituxan

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Small Cell Lung Cancer Extensive Stage

NCT05703971

Q1 2029

PreclinicalRecruiting

Carcinoma, Non-Small-Cell Lung

NCT04486833

Clinical

Trials by Indication[1]

Lung Cancer1 trial

Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer

Terminated·GGenprex, Inc.·Phase 1/2·NCT05062980·5 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer

Recruiting·GGenprex, Inc.·Preclinical·NCT04486833·158 enrolled

Small Cell Lung Cancer Extensive Stage1 trial

A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Recruiting·GGenprex, Inc.·Preclinical·NCT05703971·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for quaratusugene ozeplasmid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — quaratusugene ozeplasmid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for quaratusugene ozeplasmid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genprex, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: GGenprex, Inc.

quaratusugene ozeplasmid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q1 2029

Trials by Indication[1]

Lung Cancer1 trial

Carcinoma, Non-Small-Cell Lung1 trial

Small Cell Lung Cancer Extensive Stage1 trial

References

Drug Info

Quick Facts

Related News